The Kaur group is developing peptide-doxorubicin conjugates in order to treat triple-negative breast cancer (TNBC) by targeting cell-surface keratin-1 (K1) or epidermal growth factor receptor (EGFR) in cancer cells [22,28,29,53]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.